Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Aug 2026 → Apr 2027
See other at-risk trials from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Aug 2026 to Apr 2027
    • Eligibility criteria expanded, about 14 words
  2. Primary completion date: Jun 2026 to Aug 2026
    • Study completion date: Jun 2027 to Aug 2027
    v14
  3. Primary completion date: Dec 2028 to Jun 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 2032 to Jun 2027
    • Site details revised at 3 of 3 sites
    v13
  4. Re-verified, no change to tracked fieldsv12
  5. Collaborators expanded, about 4 wordsv11
Show 9 earlier versionsHide 9 earlier versions
  1. Primary completion date: Dec 2026 to Dec 2028
    • Study completion date: Dec 2030 to Dec 2032
    v10
  2. Primary completion date: Dec 2023 to Dec 2026
    • Study completion date: Dec 2026 to Dec 2030
    v9
  3. Primary completion date: Dec 2022 to Dec 2023
    • Study completion date: Sep 2025 to Dec 2026
    v8
  4. Re-verified, no change to tracked fieldsv7
  5. Primary completion date: Jun 2020 to Dec 2022
    • Start date: May 2014 to Jul 8, 2014
    • Study completion date: Nov 2020 to Sep 2025
    v6
  6. Re-verified, no change to tracked fieldsv5
  7. Study sites: 1 to 3v4
  8. Study completion date: Nov 2020v3
  9. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this study patients will be treated with 6 weeks of radiation therapy plus temozolomide chemotherapy according to the standard of care. However, the radiation treatment plan will be modified to deliver an higher than routine radiation dose to the subventricular zone which is an area of the brain that contains stem cells that some scientists believe may contribute to glioblastoma recurrence. The purpose of the study is to see if the tumor is controlled for a longer period of time in patients treated with this modified radiation technique than it is in patients treated with standard radiation therapy plus temozolomide chemotherapy.
Trial Details
NCT Number NCT02177578
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Reading Health System Foundation
Conditions
(from sponsor)		 Glioblastoma Multiforme
Related terms Glioblastoma
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov